Kathleen Goin Sells 4,302 Shares of Palvella Therapeutics (NASDAQ:PVLA) Stock

Palvella Therapeutics, Inc. (NASDAQ:PVLA) COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $110.73, for a total value of $476,360.46. Following the transaction, the chief operating officer owned 2,154 shares in the company, valued at approximately $238,512.42. This represents a 66.64% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Palvella Therapeutics Stock Performance

Shares of NASDAQ:PVLA opened at $118.68 on Wednesday. The company has a market cap of $1.70 billion, a P/E ratio of -28.46 and a beta of -0.15. Palvella Therapeutics, Inc. has a one year low of $20.35 and a one year high of $151.18. The business’s 50-day simple moving average is $118.24 and its 200 day simple moving average is $109.43.

Palvella Therapeutics (NASDAQ:PVLA) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). Analysts predict that Palvella Therapeutics, Inc. will post -5.26 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of PVLA. KBC Group NV bought a new stake in shares of Palvella Therapeutics in the 1st quarter valued at approximately $28,000. Group One Trading LLC lifted its stake in Palvella Therapeutics by 151.5% during the fourth quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after purchasing an additional 200 shares during the last quarter. Russell Investments Group Ltd. bought a new position in Palvella Therapeutics during the third quarter worth $36,000. JPMorgan Chase & Co. boosted its holdings in Palvella Therapeutics by 108,066.7% in the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after purchasing an additional 3,242 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Palvella Therapeutics during the second quarter valued at $85,000. Institutional investors own 40.11% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on PVLA shares. Stifel Nicolaus set a $250.00 price target on shares of Palvella Therapeutics in a research note on Tuesday, February 24th. Stephens reissued an “overweight” rating and issued a $220.00 price objective on shares of Palvella Therapeutics in a research report on Thursday, May 21st. Chardan Capital restated a “buy” rating and set a $240.00 target price on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Mizuho lifted their target price on Palvella Therapeutics from $205.00 to $250.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. Finally, HC Wainwright boosted their price target on Palvella Therapeutics from $255.00 to $270.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $199.53.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.